Overexpression of miR-375 and L-type Amino Acid Transporter 1 in Pheochromocytoma and Their Molecular and Functional Implications.

Jacopo Manso, Loris Bertazza, Susi Barollo, Alberto Mondin, Simona Censi, Sofia Carducci, Alfonso Massimiliano Ferrara, Isabella Merante Boschin, Stefania Zovato, Francesca Schiavi, Michele Gregianin, Gianmaria Pennelli, Maurizio Iacobone, Caterina Mian

Journal: International journal of molecular sciences 2022;23(5):2413

PMID: 35269556

Abstract

Pheochromocytoma (Pheo) is a tumor derived from chromaffin cells. It can be studied using 18F-dihydroxyphenylalanine (DOPA)-positron emission tomography (PET) due to its overexpression of L-type amino acid transporters (LAT1 and LAT2). The oncogenic pathways involved are still poorly understood. This study examined the relationship between F-DOPA-PET uptake and LAT1 expression, and we explored the role of miR-375 and putative target genes. A consecutive series of 58 Pheo patients were retrospectively analyzed, performing F-DOPA-PET in 32/58 patients. Real-time quantitative PCR was used to assess the expression of LAT1, LAT2, phenylethanolamine N-methyltransferase (PNMT), miR-375, and the major components of the Hippo and Wingless/Integrated pathways. Principal germline mutations associated with hereditary Pheo were also studied. Pheo tissues had significantly higher LAT1, LAT2, and PNMT mRNA levels than normal adrenal tissues. MiR-375 was strongly overexpressed. Yes-associated protein 1 and tankyrase 1 were upregulated, while beta-catenin, axin2, monocarboxylate transporter 8, and Frizzled 8 were downregulated. A positive relationship was found between F-DOPA-PET SUV mean and LAT1 gene expression and for 24 h-urinary norepinephrine and LAT1. This is the first experimental evidence of F-DOPA uptake correlating with LAT1 overexpression. We also demonstrated miR-375 overexpression and downregulated (Wnt) signaling and identified the Hippo pathway as a new potentially oncogenic feature of Pheo.

Address: Endocrinology Unit, Department of Medicine (DIMED), Padua University, 35121 Padua, Italy.; Familial Cancer Clinic and Oncoendocrinology, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy.; Nuclear Medicine Unit, Veneto Institute of Oncology IOV-IRCCS, 31100 Treviso, Italy.; Surgical Pathology and Cytopathology Unit, Department of Medicine (DIMED), Padua University, 35121 Padua, Italy.; Department of Surgical, Oncological and Gastroenterological Sciences (DiSCOG), Padua University, 35121 Padua, Italy.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.